

# Key Figures

All figures are stated in millions of € according to IFRS, unless otherwise specified	2023	Δ in %	2022	2021	2020	2019
<b>Order intake, sales revenue, and earnings</b>						
Order intake <sup>1</sup>	2,476.1	-25.3	3,314.8	3,664.4	2,381.0	1,543.5
Sales revenue	2,775.5	-20.5	3,492.7	2,887.0	1,910.1	1,440.6
Underlying EBITDA <sup>2,3</sup>	785.4	-35.7	1,221.4	1,033.4	604.7	421.5
Underlying EBITDA <sup>2,3</sup> as % of sales revenue	28.3	-6.7pp	35.0	35.8	31.7	29.3
Net profit after non-controlling interest	309.7	-64.6	876.1	414.4	335.9	234.5
Underlying net profit after non-controlling interest <sup>4</sup>	385.9	-51.6	796.6	687.8	383.8	263.0
Research and development costs	129.5	-2.2	132.4	110.5	84.5	79.2
<b>Financial data per share</b>						
Earnings per share (in €)	3.36	-64.6	9.51	4.50	3.64	2.54
Earnings per share (in €) <sup>4</sup>	4.19	-51.6	8.64	7.46	4.16	2.85
Dividend per share (in €)	0.69 <sup>5</sup>	-52.1	1.44	1.26	0.68	0.34
<b>Balance sheet</b>						
Balance sheet total	7,739.9	52.8	5,065.4	3,951.1	2,856.7	1,845.4
Equity	2,673.2	6.3	2,514.2	1,733.2	1,461.0	1,188.9
Equity ratio (in %) <sup>6</sup>	34.5	-15.1pp	49.6	43.9	51.1	64.4
<b>Financials</b>						
Capital expenditures as % of sales revenue	17.1	4.8pp	12.3	11.2	8.3	9.4
Depreciation and amortization	237.6	32.1	179.9	141.5	100.3	72.8
Cash flow from operating activities <sup>7</sup>	746.4	21.9	612.3	701.9	416.9	310.1
Net debt <sup>8</sup>	3,565.2	246.6	1,028.6	401.9	527.3	110.4
Ratio of net debt to underlying EBITDA <sup>2,3,9</sup>	4.5		0.8	0.4	0.8	0.3
<b>Total number of employees as of December 31</b>	<b>10,662</b>	<b>-10.7</b>	<b>11,934</b>	<b>10,409</b>	<b>7,566</b>	<b>6,223</b>

1 All customer orders contractually concluded and booked during the respective reporting period.

2 Earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items.

3 For more information on EBITDA, net profit, and the underlying presentation, please refer to the Group Business Development chapter and to the Glossary.

4 Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate.

5 Amount suggested by the Board of Directors (Conseil d'administration) and subject to approval by the Annual General Shareholders' Meeting.

6 Equity in relation to the balance sheet total.

7 Interest received are reported under cash flows from operating activities since fiscal 2022. The prior year figure was restated accordingly.

8 The net debt excludes the liability for the remaining purchase price for acquisitions; 2023: €80.6 million, 2022: €245.1 million, 2021: €518.7 million, 2020: €127.8 million, 2019: €72.5 million.

9 Quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period.

## Sartorius Stedim Biotech Share in Comparison to the CAC Large 60 (Indexed)

